These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4734403)

  • 21. Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement.
    Vogt W; Dieminger L; Lynen R; Schmidt G
    Hoppe Seylers Z Physiol Chem; 1974 Feb; 355(2):171-83. PubMed ID: 4215726
    [No Abstract]   [Full Text] [Related]  

  • 22. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies of the alternate pathway in chelated serum.
    Forsgren A; Mclean RH; Michael AF; Quie PG
    J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
    Ruddy S; Austen KF; Goetzl EJ
    J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in the immunochemical properties of highly purified properdin in human serum.
    Minta JO
    J Immunol; 1975 Apr; 114(4):1415-21. PubMed ID: 123262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anticomplement activity of a polyanion: pentosan sulfuric polyester. III. Mechanism of functional inactivation of the different properdin and complement system fractions].
    Berthoux FC; Freyria AM; Traeger J
    Pathol Biol (Paris); 1977 Mar; 25(3):179-84. PubMed ID: 323787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement-dependent B-cell activation by cobra venom factor and other mitogens?
    Dukor P; Schumann G; Gisler RH; Dierich M; König W; Hadding U; Bitter-Suermann D
    J Exp Med; 1974 Feb; 139(2):337-54. PubMed ID: 4589989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Properdin factor B (glycine-rich beta-glycoprotein or C3 proactivator)-polymorphism: genetic and biochemical aspects. First application to paternity cases.
    Mauff G; Hummel K; Pulverer G
    Z Immunitatsforsch Exp Klin Immunol; 1975 Oct; 150(4):327-38. PubMed ID: 129976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses.
    Pepys MB
    J Exp Med; 1974 Jul; 140(1):126-45. PubMed ID: 4545894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phospholipase A2 contamination of cobra venom factor preparations. Biologic role in complement-dependent in vivo reactions and inactivation with p-bromophenacyl bromide.
    Shaw JO; Roberts MF; Ulevitch RJ; Henson P; Dennis EA
    Am J Pathol; 1978 Jun; 91(3):517-30. PubMed ID: 655262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.
    Logue GL; Rosse WF; Adams JP
    J Clin Invest; 1973 May; 52(5):1129-37. PubMed ID: 4700488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Properdin factor D. II. Activation to D by properdin.
    Fearon DT; Austen KF; Ruddy S
    J Exp Med; 1974 Aug; 140(2):426-36. PubMed ID: 4211020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A molecular concept of the properdin pathway.
    Medicus RG; Schreiber RD; Götze O; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1976 Feb; 73(2):612-6. PubMed ID: 54923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Partial properdin deficiency.
    Davis CA; Forristal J
    J Lab Clin Med; 1980 Oct; 96(4):633-9. PubMed ID: 6903190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja).
    Eggertsen G; Lundwall A; Hellman U; Sjöquist J
    J Immunol; 1983 Oct; 131(4):1920-3. PubMed ID: 6194220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
    J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
    Adam C; Williams DG; Peters DK
    Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
    Parker CJ; White VF; Falk RJ
    Complement; 1986; 3(4):223-35. PubMed ID: 3643079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
    Ruley EJ; Forristal J; Davis NC; Andres C; West CD
    J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The complement system of man. I.
    Ruddy S; Gigli I; Austen KF
    N Engl J Med; 1972 Sep; 287(10):489-95. PubMed ID: 4114930
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.